Trial Profile
A Single Arm Pilot Study of Programmed Cell Death Drotein 1 Antibody (PD-1 SHR-1210 Combined With Apatinib Mesylate in Patients With Intermediate And Advanced-Stage Hepatocellular Carcinoma After Radical Hepatectomy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2020
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 16 Dec 2018 Status changed from not yet recruiting to recruiting.
- 02 Nov 2018 New trial record